MeiraGTx Holdings plc

MeiraGTx Holdings plc is a clinical stage gene therapy company specializing in developing treatments for ocular diseases, inherited blindness, Xerostomia following radiation treatment, degenerative diseases, neurodegenerative diseases, including amyotrophic lateral sclerosis, and Parkinson's disease. The company's clinical development programs include Phase 1/2 programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, radiation-induced Xerostomia, and Parkinson's disease. Additionally, MeiraGTx has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using proprietary riboswitch technology. The company also plans to initiate a clinical program in xerostomia related to Sjogren's syndrome and has preclinical programs in neurodegenerative diseases.

Products

• Gene therapy treatments for ocular diseases, inherited blindness, and Xerostomia

• Clinical stage programs for various diseases including Achromatopsia, Retinitis Pigmentosa, and Parkinson's disease

• Research collaboration for regulatable gene therapy treatment using proprietary riboswitch technology